Glycolytic inhibition by the knockdown of HK2 or 3BrPA treatment downregulated AKT/mTOR signaling and could be a therapeutic strategy to overcome tamoxifen resistance in BC [277]. This evidence concerns the gene AKT1 and breast cancer.